Medtronic Expects FDA Orthopedics Panel Review For InFuse Bone Graft
This article was originally published in The Gray Sheet
Executive Summary
Medtronic's Sofamor Danek division is anticipating that FDA's Orthopedics and Rehabilitation Devices Advisory Panel will review the firm's PMA submission for the use of InFuse bone graft system in spinal fusion procedures, company officials said
You may also be interested in...
Synthes Chooses Alternative-To-BMP Route In Bone Growth Factor Search
Synthes-Stratec plans to forego immediate development of an orthobiologic bone growth factor, citing doubts about the product's feasibility in musculoskeletal repair applications
Synthes Chooses Alternative-To-BMP Route In Bone Growth Factor Search
Synthes-Stratec plans to forego immediate development of an orthobiologic bone growth factor, citing doubts about the product's feasibility in musculoskeletal repair applications
Wyeth BMP-2 Should Be Limited To “Problem” Fractures – Panel
Wyeth's InductOs recombinant human bone morphogenic protein-2 indications for use should be limited to "problem" fractures, according to FDA's Orthopaedic and Rehabilitation Devices Panel